{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-108344","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.614867+00:00","generated_at":"2026-05-15T11:45:47.364416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Atara reports FY 2025 net income of $32.7M; cash runway extended through YE 2026","bullets":["Net income of $32.7M ($2.61 per share) in FY 2025 vs. net loss of $85.4M in FY 2024.","Cash, equivalents and investments $8.5M at Dec 31, 2025; net cash used in ops $50.9M in FY 2025.","Operating expenses declined sharply; expects cash plus $3.0M ATM proceeds to fund ops through YE 2026.","Pierr Fabre scheduled FDA Type A meeting for tab-cel PTLD; regulatory update expected in Q2 2026.","Milestone payment of $9.0M due to HCRx deferred from June 2026 to Jan 2028; warrant issued for 400K shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-108344","json":"https://secwatch.observer/filing/0001193125-26-108344.json","markdown":"https://secwatch.observer/filing/0001193125-26-108344.md","text":"https://secwatch.observer/filing/0001193125-26-108344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/0001193125-26-108344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/atra-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:45:47.364416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73f2c8b45745c49b6e434a5b776d1ecf0e003e97","claim":"Atara Biotherapeutics, Inc. reported the fiscal year ended December 31, 2025 results: revenue $120.8 million, net income $32.7 million, EPS $2.61 per share. Guidance initiated.","evidence_excerpt":"as compared to a net loss of ($12.7) million, or ($1.19) per share, and ($85.4) million, or ($11.41) per share, for the same periods in 2024. ● Commercialization revenues were $120.8 million in 2025 as compared to $128.9 million in 2024. ● Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of $1.6","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/0001193125-26-108344-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2025"},{"label":"Revenue","value":"$120.8 million"},{"label":"Net income","value":"$32.7 million"},{"label":"EPS","value":"$2.61 per share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7c84c5fbff33599238a98312663b047fbafc4b45","claim":"Atara Biotherapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income ($3.4) million, EPS ($0.25) per share. Guidance initiated.","evidence_excerpt":"Atara reported a net loss of ($3.4) million, or ($0.25) per share, and a net income of $32.7 million, or $2.61 per share, for the fourth quarter and fiscal year 2025, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/0001193125-26-108344-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2025"},{"label":"Net income","value":"($3.4) million"},{"label":"EPS","value":"($0.25) per share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}